PF-07338233, with the CAS number 2245880-46-8, is a small molecule that has garnered attention in pharmaceutical research, particularly for its potential as an antiviral agent. It is designed as a selective inhibitor of the SARS-CoV-2 main protease, which plays a crucial role in the viral replication process. The compound exhibits a specific binding affinity to the protease, thereby disrupting the viral life cycle. In terms of its chemical structure, PF-07338233 features a unique arrangement of functional groups that contribute to its biological activity and solubility profile. The substance is typically evaluated for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), to determine its efficacy and safety in clinical settings. Ongoing studies aim to assess its therapeutic potential against COVID-19 and other viral infections, making it a subject of interest in the field of medicinal chemistry and virology. As research progresses, further insights into its mechanism of action and potential side effects will be essential for its development as a therapeutic agent.

PF-07338233

2245880-46-8: PF-07338233, with the CAS number 2245880-46-8, is a small molecule that has garnered attention in pharmaceutical research, particularly for its potential as an antiviral agent. It is designed as a selective inhibitor of the SARS-CoV-2 main protease, which plays a crucial role in the viral replication process. The compound exhibits a specific binding affinity to the protease, thereby disrupting the viral life cycle. In terms of its chemical structure, PF-07338233 features a unique arrangement of functional groups that contribute to its biological activity and solubility profile. The substance is typically evaluated for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), to determine its efficacy and safety in clinical settings. Ongoing studies aim to assess its therapeutic potential against COVID-19 and other viral infections, making it a subject of interest in the field of medicinal chemistry and virology. As research progresses, further insights into its mechanism of action and potential side effects will be essential for its development as a therapeutic agent.

<p>Avibactam tomilopil (AV-006) is an oral prodrug of Avibactam, inhibiting class A and C β-lactamases, including ESBLs, AmpC, and KPC, antibacterial.</p>

CAS 2245880-46-8

PF-07338233

Avibactam tomilopil

Ref: TM-T39758